A phase I study investigation of metabolism, and disposition of [ 14 C]-anlotinib after an oral administration in patients with advanced refractory solid tumors

ConclusionsAnlotinib had a good pharmacokinetic profile with rapid absorption, long half-life, and extensive hepatic metabolism. The adverse events and efficacy were as expected.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research